Central vagal afferent endings mediate reduction of food intake by melanocortin-3/4 receptor agonist.

Campos CA, Shiina H, Ritter RC

The Journal of neuroscience : the official journal of the Society for Neuroscience1 Sept 2014Cited by 22 (Europe PMC)

PMID25232103PMCIDPMC4166153DOI10.1523/jneurosci.1121-14.2014PepBankPUB-25232103

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In rats, MTII increased PKA-catalyzed phosphorylation of synapsin I in vagal afferent endings in the nucleus of the solitary tract.
In plain wordsIn rats, melanotan II increased a signal (synapsin I phosphorylation) in vagal nerve endings of the hindbrain.
Peptide
Melanotan II
Outcome
IncreasePKA-catalyzed synapsin I phosphorylation in vagal afferent endings
Study
ratn: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, MTII and endogenous MC4R agonists increased protein kinase A (PKA)-catalyzed phosphorylation of synapsin I in vagal afferent endings
Report a problemFND-2523210301

Studies that did not test the peptide alone5

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

02AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome
In rats, hindbrain injection of the PKA inhibitor KT5720 significantly attenuated the MTII-induced reduction of food intake.
In plain wordsIn rats, a drug blocking PKA in the hindbrain weakened the food-intake reduction caused by melanotan II.
Peptide
Melanotan II
Outcome
DecreaseMTII-induced reduction of food intake with PKA inhibitor
Study
ratn: not reported in source
Outcome group
Appetite and food intake · Nervous system and cognition
Source sentences
Summary
Hindbrain injection of a PKA inhibitor, KT5720, significantly attenuated MTII-induced reduction of food intake
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-2523210302
03AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism
In rats, the PKA inhibitor KT5720 attenuated the MTII-induced increase in synapsin I phosphorylation.
In plain wordsIn rats, a PKA-blocking drug reduced the nerve-ending signal that melanotan II normally increases.
Peptide
Melanotan II
Outcome
DecreaseMTII-induced synapsin I phosphorylation with PKA inhibitor
Study
ratn: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Hindbrain injection of a PKA inhibitor, KT5720, significantly attenuated MTII-induced reduction of food intake and the increase in synapsin I phosphorylation
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-2523210303
04AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism
In rats, unilateral nodose ganglion removal abolished MTII-induced synapsin I phosphorylation on the same side.
In plain wordsIn rats, removing the vagal nodose ganglion on one side abolished the melanotan II nerve-ending signal on that side.
Peptide
Melanotan II
Outcome
DecreaseMTII-induced synapsin I phosphorylation after nodose ganglion removal
Study
ratn: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Finally, unilateral nodose ganglion removal, resulting in degeneration of vagal afferent endings in the ipsilateral NTS, abolished MTII-induced synapsin I phosphorylation ipsilateral to nodose ganglion removal.
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-2523210304
05AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome
In rats, the reduction of food intake after MTII injection into the NTS on the side of nodose ganglion removal was significantly attenuated.
In plain wordsIn rats, melanotan II cut food intake less when injected on the side where the vagal ganglion had been removed.
Peptide
Melanotan II
Outcome
DecreaseFood intake after MTII into NTS ipsilateral to nodose ganglion removal
Study
ratn: not reported in source
Outcome group
Appetite and food intake · Nervous system and cognition
Source sentences
Summary
Moreover, reduction of food intake following MTII injection into the NTS ipsilateral to nodose ganglion removal was significantly attenuated
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-2523210305
06AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome
In rats, the response to MTII was not diminished when it was injected into the NTS on the side opposite to nodose ganglion removal.
In plain wordsIn rats, melanotan II still worked normally when injected on the side opposite the removed vagal ganglion.
Peptide
Melanotan II
Outcome
No significant changeFood intake after MTII into NTS contralateral to nodose ganglion removal
Study
ratn: not reported in source
Outcome group
Appetite and food intake · Nervous system and cognition
Source sentences
Summary
whereas the response to MTII was not diminished when injected into the contralateral NTS.
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-2523210306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.